STAT+: A turning point for pancreatic cancer patients

STAT PlusNewsletterThe Readout A turning point for pancreatic cancer patients Eli Lilly announces two China deals, Akeso’s lung cancer bispecific payoff, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanJune 1, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. We’re catching up on plenty of ASCO news from over the weekend, including detailed daraxonrasib results in pancreatic cancer, and a Chinese lung cancer therapy that continues to outperform expectations.Advertisement Also, a decades-old peptide beloved by biohackers has become a lightning rod in a battle over FDA regulation of these substances. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech June 1, 2026 STAT Plus: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug Biotech May 31, 2026 STAT Plus: A standing ovation for RevMed, and caution for Akeso Advertisement Pharma May 31, 2026 Ultra-low doses could bring costly cancer treatments to more patients in poorer countries Biotech May 31, 2026 STAT Plus: Practice-changing results reported for Revolution Medicines pancreatic cancer drug Biotech May 31, 2026 STAT Plus: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer Subscriber Picks